Last updated on February 2019

PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in CRPC Patients Treated With Radium-223.


Brief description of study

PRORADIUM is a prospective multicentre study to analyze circulating and tissue biomarkers that may predict prognosis and response in patients with CRPC treated conventionally with Radium-223.

Detailed Study Description

This is a non-interventional prospective study in metastatic CRPC designed to explore biomarkers, composed by patients treated with Radium-223.

Key inclusion criteria: a) histological confirmation of prostate cancer; b) documented criteria (PCWG2) for CRPC; c) availability of tumour tissue; d) candidate for standard treatment with Radium-223.

Primary end point: to validate the prognostic value for overall survival (OS) of serum bone metabolism markers (BMM) described by Primo N Lara et al (JNCI 2014).

Secondary end points: a) to analyze the prognostic role for PSA response regarding to BMM; b) to correlate radiological response with BMM expression; c) to investigate the association of skeletal related events with BMM; d) to analyze the prognostic value of alkaline phosphatase before and during Radium-223; e) to study the prognostic value of "Bone Scan Index"; f) to explore the prognostic role for OS of AR-V7 and AR amplification; g) to validate the prognostic role of the expression signature described by Olmos et al (Lancet Oncol 2012) in peripheral blood.

Exploratory outcomes: a) to validate in this cohort prognostic nomograms described for CRPC; b) to explore new somatic and germinal variants in peripheral blood and tissue associated to response and resistance to Radium-223.

PRORADIUM is part of the PROCURE Biomarkers network, a multicentric spanish platform for biomarkers discovery in CRPC patients. 161 patients treated with Radium-223 will be accrued to provide appropriate statistical power to analyze the main outcome. Blood samples are collected before, during (pre-cycle 3) and after progression to Radium-223. Prospective data collection will be linked.

Clinical Study Identifier: NCT02925702

Contact Investigators or Research Sites near you

Start Over

Hospital Lluis Alcanyis

Xátiva, Spain
1.79miles

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.